Anti-cd43 antibody and use thereof for cancer treatment
AssigneeAprogen Kic Inc.
InventorsKwon Pyo HONG, Sangsoon YOON, Irene KOUKOULAS, Vincent BATORI, Briony CRISTIANO, David S. WILSON, JR., George KOPSIDAS
Life of this patent
Estimating the term…
Abstract
Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
Claims19
A method of treating a cancer or inhibiting a cancer stem cell, comprising administering a pharmaceutically effective amount of an anti-CD43 antibody or an antigen-binding fragment thereof to a subject in need of treating the cancer or inhibiting a cancer stem cell, wherein the anti-CD43 antibody or the antigen-binding fragment thereof comprises:
- a CDR1H of SEQ ID NO:
- 111,
- a CDR2H of SEQ ID NO:
- 114,
- a CDR3H of SEQ ID NO:
- 118,
- a CDR1L of SEQ ID NO:
- 119,
- a CDR2L of SEQ ID NO:
- 122, 123, or 124, and
- a CDR3L of SEQ ID NO:
- 125.
A method of inhibiting a cancer stem cell, comprising:
- administering a pharmaceutically effective amount of an anti-CD43 antibody or an antigen-binding fragment thereof to a subject in need of inhibition of a cancer stem cell, wherein the anti-CD43 antibody or the antigen-binding fragment thereof bind to an epitope consisting of 6-9 consecutive amino acids in the amino acid sequence of SEQ ID NO:
- 134, and the 6-9 consecutive amino acids comprises the amino acid sequence of SEQ ID NO:
- 131.
A method of screening an agent for inhibiting a cancer stem cell, comprising:
- contacting a candidate compound to an epitope consisting of 6-9 consecutive amino acids in the amino acid sequence of SEQ ID NO:
- 134, wherein the 6-9 consecutive amino acids comprises the amino acid sequence of SEQ ID NO:
- 131;
- and
- selecting the candidate compound that binds to the epitope, and determining the selected candidate compound as a candidate agent for inhibiting a cancer stem cell.
Dependencies are inferred from the claim text.